Business
KRTL HOLDING GROUP INC. ANNOUNCES STRATEGIC PARTNERSHIP BETWEEN KRTL BIOTECH AND AMNI PHARMACEUTICALS TO ADVANCE INTEGRATED PHARMACEUTICAL PLATFORM
KRTL HOLDING GROUP INC. ANNOUNCES STRATEGIC PARTNERSHIP BETWEEN KRTL BIOTECH AND AMNI PHARMACEUTICALS TO ADVANCE INTEGRATED PHARMACEUTICAL PLATFORM.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL Holding Group Inc. (“KRTL\r\nHolding” or the “Company”) today announced that its wholly owned subsidiary,\r\nKRTL Biotech Inc. (“KRTL Biotech”), has entered into a definitive strategic\r\npartnership with AMNI Pharmaceuticals Inc. (“AMNI”), establishing a jointly\r\ngoverned pharmaceutical platform designed to integrate manufacturing,\r\ndistribution, and future development capabilities.\r\nThe agreement outlines a\r\ncollaborative framework under which the parties will jointly develop a\r\ncompliant pharmaceutical infrastructure, including the planned establishment\r\nand registration of a 503B outsourcing facility, while emphasizing broader\r\nlong-term alignment across pharmaceutical development, commercialization, and\r\nregulated distribution channels. \r\nStrategic Partnership Overview\r\nThe partnership is structured to\r\nleverage the complementary strengths of each organization:\r\n\r\n KRTL Biotech will contribute regulatory strategy,\r\n product development capabilities, and its established FDA engagement\r\n framework, including the successful transition of its FDA Establishment\r\n Identifier (FEI) alignment to the jointly operated facility.\r\n AMNI Pharmaceuticals brings established infrastructure and\r\n holds a prescription pharmaceutical wholesale distribution license in the\r\n State of Texas, supporting compliant downstream distribution and supply\r\n chain operations.\r\n\r\nTogether, the companies intend to\r\ncreate an integrated platform capable of supporting sterile compounding\r\noperations, distribution support and future pharmaceutical development\r\ncapabilities.\r\n“This partnership represents a\r\nmeaningful step in aligning our regulatory strategy with a physical operating\r\nplatform,” said Cesar Herrera, Chief Executive Officer of KRTL Biotech. “By\r\nworking alongside AMNI, we are positioning KRTL Biotech to advance its\r\nFDA-related infrastructure within a controlled and scalable environment, while\r\nalso expanding into broader pharmaceutical opportunities.”\r\nFacility and Regulatory Alignment\r\nAs part of the collaboration,\r\noperations will be anchored at AMNI’s Texas-based facility, where the parties\r\nwill establish a jointly governed operating structure. The facility is expected\r\nto serve as the central point for regulatory execution, including FDA\r\nregistration activities ...